Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$0.83−0.01 (-0.93%)

Close on Nov 11, 2026Market cap $149.51MP/E –Yield –

Compass Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Compass Therapeutics's total debt was $0 at Dec 31, 2021. For fiscal 2021 it was $0, down 100.0% from the year before.

Period	Period end	Value	Change
FY2021	Dec 31, 2021	$0	-100.0%
FY2020	Dec 31, 2020	$9.33M	-37.2%
FY2019	Dec 31, 2019	$14.87M	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q4 FY2021	Dec 31, 2021	$0	-100.0%
Q3 FY2021	Sep 30, 2021	$3.74M	-66.5%
Q2 FY2021	Jun 30, 2021	$5.61M	-57.0%
Q1 FY2021	Mar 31, 2021	$7.47M	-49.7%
Q4 FY2020	Dec 31, 2020	$9.33M	–
Q3 FY2020	Sep 30, 2020	$11.19M	–
Q2 FY2020	Jun 30, 2020	$13.04M	–
Q4 FY2019	Dec 31, 2019	$14.87M	–

Parsed from the XBRL in Compass Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-3 split on Aug 13, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CMPX.

Advertisement
300 × 250

See a number that looks wrong?